SC
BCAX

Stempoint Capital’s Bicara Therapeutics BCAX Stock Holding History

Stempoint Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,078
Closed -$613K – 81
2025
Q1 		$613K Buy
+47,078
New +$625K 0.2% 52

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stempoint Capital's BCAX Position: Q2 2025 in Review

Stempoint Capital sold out of Bicara Therapeutics (BCAX) in Q2 2025, closing a stake of 47,078 shares — an estimated $613K sold.

Stempoint Capital first reported a position in BCAX in Q1 2025 and held it in 1 quarter. The position peaked at $613K in Q1 2025. 106 funds tracked by Wall St. Rank hold BCAX as of Q2 2025.

  • Stempoint Capital reported no remaining Bicara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stempoint Capital sold 47,078 Bicara Therapeutics shares in Q2 2025, an estimated $613K.
  • Stempoint Capital first reported a position in Bicara Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stempoint Capital's Bicara Therapeutics position peaked at $613K in Q1 2025.
  • 106 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2025.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.